Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of tafluprost and timolol.

This study will enroll patients who have ocular hypertension or glaucoma.

The study schedule includes seven visits to the study site and three stages:

• washout of 5 days to 4 weeks depending on current glaucoma medication (if any)

• 6-month study treatment period

• 1-3 weeks post-study period

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Santen Oy
• Treatments: Ophthalmic Solutions; Tetrahydrozoline; Timolol

Criteria

Inclusion Criteria:

• Aged 18 years or more

• A diagnosis of ocular hypertension or open-angle glaucoma

• Meet specific IOP level at visit 1 (screening)and visit 2 (baseline)

• Meet specific visual acuity score

• Are willing to follow instructions

• Have provided a written informed consent

Exclusion Criteria:

• Females who are pregnant, nursing or planning pregnancy

• IOP greater than 36 mmHg at any time point at screening or baseline

• Diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular or pigmentary glaucoma in either eye

• Suspected contraindication or hypersensitivity to study medications tafluprost or timolol (e.g. asthma, low pulse) or to wash-out medication brinzolamide

• Glaucoma filtration surgery or any other ocular surgery (including ocular laser procedures) within 6 months prior to Screening

• Use of contact lenses at Screening or during the study

• Presence of any abnormality or significant illness that could be expected to interfere with the patient safety or study parameters

• Current participation in another clinical trial within the last 30 days